Research Insight | Rise of the Mushrooms: Exploring Marketers' Role in the Potential Public Health Benefits of Psilocybin
Psilocybin is emerging as the next frontier in U.S. drug policy—reshaping use patterns, public health debates, and business strategy. New research using nationally representative Monitoring the Future (MTF) data shows that, in states with psilocybin reforms, young adults are choosing psilocybin over LSD and MDMA.
This shift has significant health implications. Compared to LSD and MDMA, psilocybin carries lower risks of dependency and adverse outcomes, while showing strong therapeutic potential in treating depression, anxiety, and compulsive disorders. A move toward psilocybin use could reduce ER visits, lower public health costs, and improve patient outcomes. Still, consumer confusion persists. For example, many in Oregon mistakenly equate supervised psilocybin service centers with cannabis dispensaries, highlighting the need for education.
From a business perspective, psilocybin is poised to disrupt the $70B mental health therapeutics market, with $730M already invested in psychedelic ventures. Yet, commercialization ahead of clear regulation risks safety issues, inequitable access, and public mistrust. Companies should get ahead by supporting education, training facilitators, adopting tiered pricing, and collaborating with policymakers.
Psilocybin reforms are already reshaping consumer behavior, and coordinated oversight, transparency, and research will be critical to unlock their full potential.
For more Research Insights, click here.
What You Need to Know
- Align with Regulation and Clinical Standards: As psilocybin gains policy traction, firms should support clear safety guidelines, facilitator training, and evidence-based protocols to ensure responsible market development.
- Invest in Credible Communication: Differentiate supervised therapy from broader drug use through public education, transparent messaging, and collaboration with healthcare professionals.
- Expand Access Responsibly: To avoid equity issues and gray markets, consider pricing models, insurance coverage, and nonprofit partnerships that make treatment more affordable.
Abstract
This study examines the relationship between psilocybin reforms and usage patterns of prevalent psychedelics in the United States. Given decriminalization efforts in several cities and legalization in Oregon, the authors analyze drug use panel data from University of Michigan’s Monitoring the Future project to assess changes in self-reported use of psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA, commonly referred to as Molly or Ecstasy). The findings reveal a substitution pattern from LSD and MDMA to psilocybin associated with psilocybin reforms. Given the potential therapeutic benefits of psilocybin and its lower associated risks than LSD and MDMA, the findings suggest a possible public health benefit associated with psilocybin reforms. Moreover, with the increased interest from venture capitalists in the psilocybin-related drug market, this study discusses important topics such as consumer safety and advises caution.